BeOne Medicines (NASDAQ:ONC) Shares Down 4.5% – Should You Sell?

Shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) fell 4.5% on Monday . The company traded as low as $322.41 and last traded at $332.16. 347,042 shares traded hands during trading, a decline of 11% from the average session volume of 388,412 shares. The stock had previously closed at $347.72.

Analyst Ratings Changes

Several equities analysts have commented on ONC shares. Citigroup increased their target price on BeOne Medicines from $399.00 to $405.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research report on Wednesday, October 8th. Guggenheim boosted their target price on shares of BeOne Medicines from $350.00 to $365.00 and gave the stock a “buy” rating in a report on Thursday, August 7th. JPMorgan Chase & Co. raised their price target on shares of BeOne Medicines from $345.00 to $385.00 and gave the company an “overweight” rating in a research note on Wednesday, October 8th. Finally, Royal Bank Of Canada lifted their price target on shares of BeOne Medicines from $395.00 to $408.00 and gave the stock an “outperform” rating in a report on Tuesday, November 18th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, BeOne Medicines currently has a consensus rating of “Moderate Buy” and an average target price of $365.79.

BeOne Medicines Stock Performance

The stock has a market capitalization of $39.44 billion, a price-to-earnings ratio of 652.37 and a beta of 0.31. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39. The stock has a fifty day simple moving average of $332.31 and a two-hundred day simple moving average of $296.54.

Insider Transactions at BeOne Medicines

In other news, Director Corazon (Corsee) D. Sanders sold 2,665 shares of BeOne Medicines stock in a transaction on Friday, September 5th. The shares were sold at an average price of $337.00, for a total value of $898,105.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO John Oyler sold 27,803 shares of the stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $325.71, for a total transaction of $9,055,715.13. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 81,254 shares of company stock valued at $27,971,587. 6.62% of the stock is owned by insiders.

Hedge Funds Weigh In On BeOne Medicines

Several institutional investors have recently made changes to their positions in the stock. Anchor Investment Management LLC acquired a new stake in shares of BeOne Medicines in the 2nd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd acquired a new stake in BeOne Medicines in the second quarter valued at approximately $28,000. Daiwa Securities Group Inc. bought a new stake in shares of BeOne Medicines during the second quarter valued at approximately $35,000. Farther Finance Advisors LLC bought a new stake in shares of BeOne Medicines during the second quarter valued at approximately $39,000. Finally, Signaturefd LLC acquired a new position in shares of BeOne Medicines during the second quarter worth approximately $49,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.